Grifols (GIKLY) Cash from Financing Activities (2010 - 2020)
Grifols (GIKLY) posted Cash from Financing Activities of -$121.5 million for Q1 2020, up 54.2% quarter-over-quarter from -$265.2 million in Q4 2019, and down 93.07% year-on-year from -$1.8 billion in Q2 2019.
Grifols (GIKLY) Cash from Financing Activities (2010 - 2020) Analysis & Trends
Grifols (GIKLY) has reported Cash from Financing Activities for 10 consecutive years, with -$121.5 million the latest figure, recorded in Q1 2020.
- Cash from Financing Activities for Q1 2020 came in at -$121.5 million, down 93.07% year-over-year; the trailing twelve-month figure through Mar 2020 was -$356.2 million (down 120.86% YoY), and the FY2025 annual result was -$615.8 million, up 57.6% from the prior year.
- Cash from Financing Activities was -$121.5 million for Q1 2020 at Grifols, up from -$265.2 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $1.8 billion in Q4 2017 and troughed at -$265.2 million in Q4 2019.
- Average Cash from Financing Activities over 5 years is $236.6 million, with a median of -$62.9 million recorded in 2019.
- Year-over-year, Cash from Financing Activities soared 1301.8% in 2017 and sank 503.89% in 2019.
- Over 5 years, Cash from Financing Activities stood at -$146.6 million in 2016, then soared by 1301.8% to $1.8 billion in 2017, then sank by 94.7% to $93.4 million in 2018, then sank by 383.88% to -$265.2 million in 2019, then soared by 54.2% to -$121.5 million in 2020.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$121.5 million in Q1 2020, -$265.2 million in Q4 2019, and -$62.9 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -3.47 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 530.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 919.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 267.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -2.98 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.44 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -4.24 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -2.86 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -121.48 Mn |
| Mar 31, 2020 | -121.48 Mn |
| Dec 31, 2019 | -265.22 Mn |
| Dec 31, 2019 | -265.22 Mn |
| Mar 31, 2019 | -62.92 Mn |
| Mar 31, 2019 | -62.92 Mn |
| Dec 31, 2018 | 93.43 Mn |
| Dec 31, 2018 | 93.43 Mn |
| Jun 30, 2018 | -207.36 Mn |
| Jun 30, 2018 | -207.36 Mn |
| Mar 31, 2018 | 15.58 Mn |
| Mar 31, 2018 | 15.58 Mn |
| Dec 31, 2017 | 1.76 Bn |
| Dec 31, 2017 | 1.76 Bn |
| Jun 30, 2017 | -97.45 Mn |
| Jun 30, 2017 | -97.45 Mn |
| Mar 31, 2017 | 1.67 Bn |
| Mar 31, 2017 | 1.67 Bn |
| Dec 31, 2016 | -146.57 Mn |
| Dec 31, 2016 | -146.57 Mn |